Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot etc. |
| Sample | BC tissues, cell lines (MDA-MB-231, MCF-7, SKBR3, MCF-10A) |
| Expression Pattern | down-regulated |
| Function Description | MEG3 was significantly down-regulated in breast cancer tissues compared to adjacent normal tissues.MEG3/miR-421/E-cadherin regulatory axis may be a novel therapeutic target for breast cancer.endogenous miR-421 expression was negatively regulated by MEG3 in breast cancer cells and MEG3 regulated E-cadherin expression by sponging to miR-421 in breast cancer cells.Survival analysis showed that lower MEG3 predicted a poor DFS and OS for patients. Down-regulation of MEG3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/b-catenin signaling pathway. |
| Pubmed ID | 28463794 |
| Year | 2017 |
| Title | LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer. |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |